Leukemia
In recent years, the field of oncology has witnessed groundbreaking advancements, particularly in the realm of CAR-T (Chimeric Antigen Receptor T-cell) therapy.
#### New Breakthrough in CAR-T Cell Research in China: Type 2 T Cell Function Supports Long-term Leukemia Remission #CAR-T #Leukemia #Type2TCells #ALL #GATA3 In recent years, China has achieved significant progress in CAR-T cell therapy, particularly in treating acute lymphoblastic leukemia (ALL). CD19-targeted CAR-T cell therapy has provided new hope for curing patients with relapsed or refractory Read More
Groundbreaking Chinese CAR-T Research: CD5 CAR-T Therapy Brings New Hope for Relapsed/Refractory T-cell Acute Lymphoblastic Leukemia (T-ALL) Relapsed or refractory acute T-cell lymphoblastic leukemia (r/r T-ALL) has long lacked effective treatment options, with a poor prognosis. Although CD7 CAR-T therapy has shown some efficacy, many patients experience relapse due to CD7 antigen loss. #CAR-T #TALL #ALL #CARTtherapy #leukemia Read More
**Breakthrough in China’s CAR-T Therapy for Treating Relapsed B-ALL: Donor-Derived CD19 CAR-T Shows Long-Term Survival Advantage** #CAR_TTherapy #B_ALL #DonorCAR_T #CAR_T #ALL #ChinaCART #CD19 #alloHSCT In recent years, China has made significant strides in CAR-T cell therapy, particularly in treating B-cell acute lymphoblastic leukemia (B-ALL). Donor-derived CAR-T therapy has shown promising efficacy for B-ALL patients who Read More
China’s CAR-T Therapy: A Beacon of Hope for Children with Acute Lymphoblastic Leukemia (ALL) #CARTTherapy #Leukemia #ChildhoodCancer #ALL #CART #AcuteLymphoblasticLeukemia #Patientstory China’s CAR-T cell therapy is emerging as a beacon of hope in the fight against cancer, bringing unprecedented treatment possibilities. As a precise cellular immunotherapy, CAR-T therapy enhances the cancer-fighting abilities of T-cells through genetic editing technology, Read More
**China’s New CAR-T Therapy: Bringing New Hope for Acute Myeloid Leukemia (AML)** #CLL1CART #AML #Leukemia #CART #CARTtherapy #AcuteMyeloidLeukemia #CLL1 #CD371 In recent years, China’s rise in the field of medical innovation has been remarkable, especially with breakthroughs in cancer and hematologic malignancy treatments that are drawing global attention. Today, we are introducing a cutting-edge treatment from China—donor-derived CLL-1 Read More
### Significant Progress in CAR-T Therapy in China: Long-Term Effects of Combined CD19 and CD22 Treatment for Acute B-Lymphoblastic Leukemia #ALL #CAR-Ttherapy #Leukemia #CancerResearch #B_ALL #LeukemiaTreatment Recently, a Chinese medical team published a notable study titled “Five-year outcome of CD19 combined with CD22 CAR-T cell therapy in B-ALL patients relapsed after allo-transplantation.” The research highlights Read More
Another New CAR-T Therapy in China is Fast-Tracking Approval, Targeting Pediatric Acute Lymphoblastic Leukemia with a 100% Response Rate! #ALL #AcuteLymphoblasticLeukemia #Leukemia #CART #CARTtherapy In recent years, CAR-T cell therapies from China have garnered global attention in the fight against cancer, and now another CAR-T product is about to hit the market. Priscabtagene Autoleucel Injection Read More